Cytokinetics Launches MYQORZO, Entering Commercial Biopharma Realm
Event summary
- Cytokinetics launched MYQORZO (aficamten) in the U.S. on January 27, 2026, following FDA approval on December 19, 2025.
- MYQORZO is indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
- The drug is a cardiac myosin inhibitor, a novel mechanism of action for treating oHCM.
- MYQORZO is available in four dosages (5mg, 10mg, 15mg, 20mg) and is subject to a Risk Evaluation and Mitigation Strategy (REMS) program due to potential heart failure risks.
The big picture
Cytokinetics' launch of MYQORZO marks a significant transition for the company, moving from a research-focused entity to a commercial biopharmaceutical player. The drug addresses a relatively niche market (oHCM affecting ~500,000 patients in the U.S.), but its novel mechanism of action and lack of direct competition create a potential for substantial revenue generation. However, the stringent REMS requirements and the inherent risks associated with cardiac therapies will necessitate careful management and ongoing monitoring.
What we're watching
- REMS Compliance
- The success of MYQORZO’s commercialization hinges on adherence to the REMS program, and any breaches or modifications could significantly impact market access and sales.
- Competitive Landscape
- While MYQORZO represents a novel approach, the emergence of alternative therapies or competing mechanisms of action could erode its market share over time.
- Clinical Expansion
- The progression of clinical trials (ACACIA-HCM, CEDAR-HCM, FOREST-HCM) will determine the potential for expanding MYQORZO’s indication to non-obstructive HCM and pediatric populations, impacting long-term revenue potential.
Related topics